January 28, 2025 09:53 AM EST
News Briefing

Akero, 89bio dis­close pub­lic of­fer­ings; BioAge drops Phase 2 obe­si­ty drug

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Plus, news about Vigonvi­ta Life Sci­ences and Lutris Phar­ma:

For MASH de­vel­op­ers, a race for cash: Akero Ther­a­peu­tics aims to raise …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da CEO Christophe We­ber to re­tire in June 2026, Julie Kim to take over

Roche aims for de­risked deals and ruth­less port­fo­lio cuts in 2025

Sanofi is in the mar­ket for M&A, thanks to ‘strong’ bal­ance sheet

Mer­ck stops an­oth­er Win­re­vair study ear­ly based on pos­i­tive re­sults from ear­li­er PAH tri­al

In­hibikase shelves Parkin­son’s as­set af­ter Phase 2 flop

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times